Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes

Experimental and Molecular Medicine

Volumn 44, Issue 11, 2012, Pages 665-673

  Kim, Kyoung Soo ^a   Oh, Da Hee ^a   Kim, Jung Yeon ^b   Lee, Bong Gn ^a   You, Jeong Soon ^c   Chang, Kyung Ja ^c   Chung, Hyunju ^a   Yoo, Myung Chul ^a   Yang, Hyung In ^a   Kang, Ja Heon ^a   Hwang, Yoo Chul ^a   Ahn, Kue Jeong ^a   Chung, Ho Yeon ^a   Jeong, In Kyung ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Inha University   (South Korea)

Author keywords

Diabetes mellitus; Dyslipidemias; Hyperglycemia; Long Evans; Rats; Taurine; Type 2

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAURINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MORPHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RAT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84869820580     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2012.44.11.075     Document Type: Article

References (38)

1. Bieri J, Stoewsand G, Briggs G, Phillips, Woodard RJ, Knapka J. Report of the American Institute of Nurtition ad hoc Committee on Standards for Nutritional Studies. J Nutr 1977; 107:1340-8
2. Brons C, Spohr C, Storgaard H, Dyerberg J, Vaag A. Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur J Clin Nutr 2004;58:1239-47
3. Bruns H, Watanpour I, Gebhard MM, Flechtenmacher C, Galli U, Schulze-Bergkamen H, Zorn M, Buchler MW, Schemmer P. Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study. Microcirculation 2011;18:205-13
4. Chen X, Sebastian BM, Tang H, McMullen MM, Axhemi A, Jacobsen DW, Nagy LE. Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology 2009;49: 1554-62
5. Das J, Vasan V, Sil PC. Taurine exerts hypoglycemic effect in alloxan-induced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis. Toxicol Appl Pharmacol 2012;258:296-308
6. El Mesallamy HO, El-Demerdash E, Hammad LN, El Magdoub HM. Effect of taurine supplementation on hyperhomocysteinemia and markers of oxidative stress in high fructose diet induced insulin resistance. Diabetol Metab Syndr 2010;2:46
7. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599-622
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
9. Gulcelik NE, Usman A, Gurlek A. Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 2009;36:397-403
10. Haber CA, Lam TK, Yu Z, Gupta N, Goh T, Bogdanovic E, Giacca A, Fantus IG. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab 2003; 285:E744-53
11. Han J, Bae JH, Kim SY, Lee HY, Jang BC, Lee IK, Cho CH, Lim JG, Suh SI, Kwon TK, Park JW, Ryu SY, Ho WK, Earm YE, Song DK. Taurine increases glucose sensitivity of UCP2-overexpressing beta-cells by ameliorating mitochondrial metabolism. Am J Physiol Endocrinol Metab 2004;287: E1008-18
12. Hansen SH, Andersen ML, Cornett C, Gradinaru R, Grunnet N. A role for taurine in mitochondrial function. J Biomed Sci 2010;17 Suppl 1:S23
13. Holland WL, Brozinick JT, Wang LP, Hawkins ED, Sargent KM, Liu Y, Narra K, Hoehn KL, Knotts TA, Siesky A, Nelson DH, Karathanasis SK, Fontenot GK, Birnbaum MJ, Summers SA. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulinresistance. Cell Metab 2007;5:167-79
14. Hoogwerf BJ, Sferra J, Donley BG. Diabetes mellitus-overview. Foot Ankle Clin 2006;11:703-15
15. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-7
16. Ikubo N, Saito M, Tsounapi P, Dimitriadis F, Ohmasa F, Inoue S, Shimizu S, Kinoshita Y, Satoh K. Protective effect of taurine on diabetic rat endothelial dysfunction. Biomed Res 2011;32: 187-93
17. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaBalpha. Diabetes 2002;51:2005-11
18. Ito T, Schaffer SW, Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 2012;42:1529-39
19. Jeong IK, King GL. New perspectives on diabetic vascular complications: the loss of endogenous protective factors induced by hyperglycemia. Diabetes Metab J 2011;35:8-11
20. Kaniuk NA, Kiraly M, Bates H, Vranic M, Volchuk A, Brumell JH. Ubiquitinated-protein aggregates form in pancreatic beta-cells during diabetes-induced oxidative stress and are regulated by autophagy. Diabetes 2007;56:930-9
21. Kim SJ, Gupta RC, Lee HW. Taurine-diabetes interaction: from involvement to protection. Curr Diabetes Rev 2007;3: 165-75
22. Kim DY, Yuan HD, Chung IK, Chung SH. Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. J Agric Food Chem 2009;57:1532-7
23. Lee E, Ryu GR, Ko SH, Ahn YB, Yoon KH, Ha H, Song KH. Antioxidant treatment may protect pancreatic beta cells through the attenuation of islet fibrosis in an animal model of type 2 diabetes. Biochem Biophys Res Commun 2011;414: 397-402
24. Leung N, Sakaue T, Carpentier A, Uffelman K, Giacca A, Lewis GF. Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 h of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. Diabetologia 2004;47: 204-13
25. Lourenco R, Camilo ME. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr Hosp 2002;17:262-70
26. Masquio DC, de Piano A, Sanches PL, Corgosinho FC, Campos RM, Carnier J, Silva PL, Caranti DA, Tock L, Oyama LM, Nascimento CM, de Mello MT, Tufik S, Damaso AR. The effect of weight loss magnitude on pro/anti-inflammatory adipokines and carotid intima-media thickness in obese adolescents engaged in interdisciplinary weight-loss therapy. Clin Endocrinol (Oxf) 2012 [Epub ahead of print]
27. Murakami S, Yamagishi I, Asami Y, Ohta Y, Toda Y, Nara Y, Yamori Y. Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology 1996;52: 303-13
28. Nakaya Y, Minami A, Harada N, Sakamoto S, Niwa Y, Ohnaka M. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous type 2 diabetes. Am J Clin Nutr 2000;71:54-8
29. Oprescu AI, Bikopoulos G, Naassan A, Allister EM, Tang C, Park E, Uchino H, Lewis GF, Fantus IG, Rozakis-Adcock M, Wheeler MB, Giacca A. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes 2007;56: 2927-37
30. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-61
31. Schaffer SW, Azuma J, Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 2009; 87:91-9
32. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45:988-91
33. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-6
34. Tokunaga H, Yoneda Y, Kuriyama K. Streptozotocin-induced elevation of pancreatic taurine content and suppressive effect of taurine on insulin secretion. Eur J Pharmacol 1983; 87:237-43
35. Wang LJ, Yu YH, Zhang LG, Wang Y, Niu N, Li Q, Guo LM. Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: correlated with downregulation of LOX-1 and ICAM-1 expression on aortas. Eur J Pharmacol 2008;597:75-80
36. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19: 65-76
37. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6
38. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95